Carlos Rubio Terrés-rekin lankidetzan egindako argitalpenak (1)

2021

  1. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 2, pp. 285-297